Terumo Corporation

Terumo Corporation reported record-high quarterly revenue of JPY311.8 billion, up 9% on a local currency basis, driven by strong global demand, particularly in the Americas. Operating profit surged 60% year-on-year to JPY89.5 billion, boosted by a JPY13 billion US tariff refund and JPY20 billion in one-time settlement proceeds, with adjusted operating profit up 35%. The Cardiac and Vascular company achieved 7% local currency revenue growth, led by strong demand for Transcatheter Heart Valve Systems and robust Neuro business performance, especially in China, Japan, and Europe. Full-year profit guidance was revised upward, incorporating the tariff refund and settlement proceeds, while the revenue outlook remained unchanged at JPY1.239 trillion, with expectations of record highs in both revenue and profit for fiscal year 2026.

The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, at a compound annual growth rate of 7.9%. Disposables hold the largest product share, driven by recurring demand from blood collection and therapeutic procedures. Plasmapheresis leads by procedure, supported by rising demand for plasma-derived therapies and increasing plasma donations. North America maintained the largest regional market share in 2025, reflecting high disease prevalence and broad adoption of apheresis technologies. Key players include Terumo Corporation, Fresenius SE & Co. KGaA, Haemonetics Corporation, and Becton, Dickinson and Company.

The global IV equipment market is projected to grow from USD 17.82 billion in 2026 to USD 23.92 billion by 2031, at a compound annual growth rate of 6.1%. Growth is driven by the rising prevalence of chronic diseases, increasing demand for hospital services, and a shift toward home-based and outpatient care. The needle-free connectors and extension sets segment is expected to see remarkable growth due to enhanced safety features and reduced needlestick injuries, while medication administration remains the dominant application. North America leads the regional market, supported by a strong healthcare infrastructure and high adoption of advanced technologies. Key players include Becton, Dickinson and Company, B. Braun SE, Fresenius SE & Co. KGaA, ICU Medical, Inc., and Terumo Corporation.

The global therapeutic apheresis market is projected to grow from USD 3.84 billion in 2025 to USD 8.94 billion by 2035, at a compound annual growth rate of 7.9%, according to a new report by Healthcare Foresights. The market was valued at approximately USD 4.18 billion in 2026. Growth is driven by the rising prevalence of chronic and autoimmune diseases, technological advancements in automated apheresis systems, and expanding applications in regenerative medicine and CAR-T therapies. North America currently holds the largest market share, while the Asia Pacific region is expected to exhibit the highest growth rate due to increasing healthcare spending and infrastructure investments. Key players include Terumo BCT, Fresenius Kabi, Haemonetics, and B. Braun Melsungen.

IceCure Medical highlighted a newly published peer-reviewed journal article demonstrating key clinical advantages of its ProSense cryoablation over radiofrequency ablation for early-stage breast cancer. The article, published in the International Journal of Surgery, which is ranked third globally among surgical journals, was authored by leading Japanese breast cancer specialists and reports that thermal ablation technologies have shown local tumor control rates comparable to breast-conserving surgery for appropriately selected patients with small breast tumors, while offering shorter procedures, minimal scarring, and improved cosmetic outcomes. The publication notes that cryoablation can be performed under local anesthesia, unlike radiofrequency ablation which requires general anesthesia, and allows flexible adjustment of the ice ball size with visible margins, whereas radiofrequency ablation is harder to control. IceCure is preparing for the 34th Annual Meeting of the Japanese Breast Cancer Society in Kyoto on June 25-27, 2026, and its exclusive distributor in Japan, Terumo Corporation, one of the world's top 20 medical device companies, is expected to submit ProSense for regulatory approval in breast cancer to Japan's Pharmaceuticals and Medical Devices Agency in the second half of 2026.